Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978

ENANTA PHARMACEUTICALS INC

Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.
Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).
Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.
Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.
Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-216735

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.